Rosi v. Aclaris Therapeutics, Inc.

District Court, S.D. New York·Decided December 9, 2021·No. 1:19-cv-07118-LJL·Unknown

Opinion

USDC SDNY DOCUMENT UNITED STATES DISTRICT COURT ELECTRONICALLY FILED SOUTHERN DISTRICT OF NEW YORK DOC #: Sonnac nnn ence nnnnns IK DATE FILED:_12/09/2021 LINDA ROSI, individually and on behalf of all others : similarly situated, : : 19-cv-7118 (LJL) Plaintiff, : 19-cv-8284 (LJL) -v- : OPINION AND ORDER ACLARIS THERAPEUTICS, INC., et al., : Defendants. : wn ee KX LEWIS J. LIMAN, United States District Judge: Lead plaintiff Robert Fulcher (“Lead Plaintiff,” “Plaintiff,” or “Fulcher’”) moves for final approval of a class-action settlement in the amount of $2.65 million. Specifically, Fulcher moves for an order certifying a settlement class of all persons or entities that purchased or otherwise acquired Aclaris Therapeutics, Inc. (“Aclaris” or “Company”) securities between May 8, 2018 and August 12, 2019, inclusive; for final approval of the settlement for $2.65 million in exchange for releases; for attorneys’ fees and expenses; and for a service award! for named plaintiff Fulcher. Dkt. No. 67. The settlement is approved, with modifications to the attorneys’ fee award and the service award.” BACKGROUND Plaintiff brings this action under Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder against Aclaris, a small physician-led biopharmaceutical

' Fulcher refers to an “incentive award,” but the award he seeks is more properly referred to as a “service award.” The Court uses the latter locution throughout this opinion. ? Simultaneous with this opinion and order, the Court is approving the settlement of the parallel shareholder derivative action against the officers and directors of Aclaris. See Allred v. Walker et al, 19-cv-10641 (S.D.N.Y.).

company headquartered in Wayne, Pennsylvania, and certain of its current or former officers (“Individual Defendants” and collectively with Aclaris, “Defendants”). The operative complaint alleges that Aclaris and the Individual Defendants violated Section 10(b) of the Exchange Act by making certain statements that Plaintiff alleges were false and misleading primarily about Aclaris’s first FDA-approved product, ESKATA. Plaintiff’s allegations are more fully described

in the Court’s opinion and order granting in part and denying in part Defendants’ motion to dismiss, familiarity with which is assumed. Lead counsel is the law firm of Pomerantz LLP. On March 29, 2021, the Court granted in part and denied in part Defendants’ motion to dismiss the complaint for failure to state a claim and for failure to plead fraud with particularity. Rosi v. Aclaris Therapeutics, Inc., 2021 WL 1177505 (S.D.N.Y. Mar. 29, 2021). In particular, the Court sustained the complaint to the extent it alleged fraud with respect to statements made by the Company in August and November 2018 touting its direct-to-consumer advertising campaign as the course of ESKATA’s likely future success without revealing that the FDA had previously written the Company that it believed the marketing campaign was misleading and

would attempt to enjoin it. The Court rejected the remainder of Plaintiff’s claims. The proposed settlement provides for Aclaris or its insurers to pay $2.65 million into a settlement fund from which attorneys’ fees will be paid to Plaintiff’s counsel and a service award will be paid to Fulcher, both in amounts to be determined by the Court, and the remainder used to pay costs of administration or distributed to class member’s based on a computation of their recognized loss. In exchange, the lawsuit will be dismissed and class members who do not opt out of the settlement will be bound by a broad release of all claims arising out of or that are based upon or relate in any way to the purchase, acquisition, sale or ownership of Aclaris securities during the settlement class period. Dkt. No. 62-1. On August 18, 2021, the Court entered an order preliminarily approving the settlement and providing for notice. Dkt. No. 66. Among other things, the Court certified, solely for purposes of settlement, a settlement class consisting of all persons or entities that purchased or otherwise acquired Aclaris securities between May 8, 2018 and August 12, 2019, inclusive (the “Settlement Class Period”). Id. The Court also preliminarily approved the settlement as being

fair, reasonable, and adequate to the settlement class, subject to further consideration at the settlement hearing, approved the form and plan of notice, and scheduled a deadline for opt-outs and objections and for the final settlement hearing. Id. The settlement administrator sent 9,211 notice packages to potential settlement class members and their nominees. No objections to the settlement have been received. There has been only one opt-out. DISCUSSION In addition to approval of the $2.65 million class-action settlement, lead counsel moves for a fees award of $833,333.33, which is 33.3% of the settlement fund. Lead counsel also seeks reimbursement of $55,255.76 in out-of-pocket litigation expenses and a service award of

$10,000 for class representative Fulcher to be paid from the settlement fund. The Court first confirms its findings certifying the settlement class. It then turns to the fairness, reasonableness, and adequacy of the proposed settlement. Finally, it turns to the request for attorneys’ fees and a service award. I. Certification of the Settlement Class In its order of August 18, 2021, the Court certified the settlement class under Rules 23(a) and 23(b)(3) of the Federal Rules of Civil Procedure. Dkt. No. 66. The Court now confirms that ruling. The settlement class satisfies the threshold requirements of Rule 23(a), including numerosity, commonality of questions of law and fact, whether the claims of the named plaintiffs are typical of the class, and whether the representative parties adequately represent the class’s interest. The Court finds that the class is so numerous that joinder of all members is impracticable. There were more than 41.2 million shares of Aclaris common stock outstanding

at the end of the Settlement Class Period and an average daily trading volume in the United States of 516,759 shares during the Settlement Class Period. Dkt. No. 61 at 17. The proposed class satisfies the requirement that its members have common questions of law and fact. Common questions include whether Defendants’ statements were false and material, whether they were misleading, whether Defendants acted with scienter, and transaction and loss causation. See, e.g., In re Oxford Health Plans, Inc., Sec. Litig., 191 F.R.D. 369, 374 (S.D.N.Y. 2000). The claims of Lead Plaintiff are typical of the claims that would be raised by all members of the class. A plaintiff’s claim is typical if it arises from “the same course of events and each

Free access — add to your briefcase to read the full text and ask questions with AI

Rosi v. Aclaris Therapeutics, Inc., (S.D.N.Y. 2021).

Rosi v. Aclaris Therapeutics, Inc. (Rosi v. Aclaris Therapeutics, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Charron v. Wiener
731 F.3d 241 (Second Circuit, 2013)
In Re Flag Telecom Holdings Securities Litigation
574 F.3d 29 (Second Circuit, 2009)
Silberblatt v. Morgan Stanley
524 F. Supp. 2d 425 (S.D. New York, 2007)
Roberts v. Texaco, Inc.
979 F. Supp. 185 (S.D. New York, 1997)
In Re Union Carbide Consumer Prod. Bus. SEC. Lit.
724 F. Supp. 160 (S.D. New York, 1989)
Weseley v. Spear, Leeds & Kellogg
711 F. Supp. 713 (E.D. New York, 1989)
Maley v. Del Global Technologies Corp.
186 F. Supp. 2d 358 (S.D. New York, 2002)
In Re Metlife Demutualization Litigation
689 F. Supp. 2d 297 (E.D. New York, 2010)
Becher v. Long Island Lighting Co.
64 F. Supp. 2d 174 (E.D. New York, 1999)
Goldberger v. Integrated Resources, Inc.
209 F.3d 43 (Second Circuit, 2000)
Wal-Mart Stores, Inc. v. Visa U.S.A. Inc.
396 F.3d 96 (Second Circuit, 2005)
Washenik v. Public Pension Funds
772 F.3d 125 (Second Circuit, 2014)
In re Oxford Health Plans, Inc.
191 F.R.D. 369 (S.D. New York, 2000)
City of Detroit v. Grinnell Corp.
560 F.2d 1093 (Second Circuit, 1977)